Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, United States
Cancer treatment center in Bemidji, Minnesota
1233 34th St NW, Bemidji, MN 56601
About Sanford Joe Lueken Cancer Center
"The Joe Lueken Cancer Center in Bemidji, MN provides a patient-centered home for healing. We are the region’s largest medical facility offering comprehensive cancer and blood disorder care."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
National Cancer Institute (NCI)
100
Alliance for Clinical Trials in Oncology
25
SWOG Cancer Research Network
18
ECOG-ACRIN Cancer Research Group
16
NRG Oncology
13
Gynecologic Oncology Group
5
Wake Forest University Health Sciences
5
GOG Foundation
3
Radiation Therapy Oncology Group
2
Canadian Cancer Trials Group
1
National Heart, Lung, and Blood Institute (NHLBI)
1
Clinical Trials at Sanford Joe Lueken Cancer Center
During the past decade, Sanford Joe Lueken Cancer Center conducted 138 clinical trials. In the 10-year time frame, 138 clinical trials started and 55 clinical trials were completed, i.e. on
average, 39.9% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 38 clinical trials were completed. i.e. 97.4%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
2003-08-25
2021-01-05
Completed
1,381
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
2005-08-04
2022-12-01
Active, not recruiting
3,610
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
2006-04-07
2030-09-30
Active, not recruiting
10,273
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
2007-06-01
2023-10-16
Active, not recruiting
1,501
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
2006-04-24
2021-09-01
Completed
1,943
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
2007-11-02
Active, not recruiting
4,994
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
2007-12-06
Active, not recruiting
1,052
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
2008-02-29
Active, not recruiting
306
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Sanford Joe Lueken Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 100 trials, followed by "Alliance for Clinical Trials in Oncology" with 25 trials
sponsored, "SWOG Cancer Research Network" with 18 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 16 trials sponsored and "NRG Oncology"
with 16 trials sponsored. Other sponsors include 12 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Sanford Joe Lueken Cancer Center"
#1 collaborator was "National Cancer Institute (NCI)" with 87 trials as a collaborator, "NRG Oncology" with 28 trials as a collaborator, "Canadian Cancer Trials Group" with 9 trials as a collaborator, "SWOG Cancer Research Network" with 5 trials as a collaborator and "Cancer and Leukemia Group B" with 4 trials as a collaborator. Other collaborators include 22 different institutions and companies that were
collaborators in the rest 27 trials.
Clinical Trials Conditions at Sanford Joe Lueken Cancer Center
According to Clinical.Site data, the most researched conditions in "Sanford Joe Lueken Cancer Center" are
"Stage IV Lung Cancer AJCC v8" (10 trials), "Recurrent Ovarian Carcinoma" (9 trials), "Recurrent Breast Carcinoma" (8 trials), "Recurrent Fallopian Tube Carcinoma" (8 trials) and "Recurrent Primary Peritoneal Carcinoma" (8 trials). Many other conditions were trialed in "Sanford Joe Lueken Cancer Center" in a lesser frequency.
Clinical Trials Intervention Types at Sanford Joe Lueken Cancer Center
Most popular intervention types in "Sanford Joe Lueken Cancer Center" are "Drug" (143 trials), "Other" (125 trials), "Biological" (74 trials), "Procedure" (60 trials) and "Radiation" (48 trials). Other intervention types were less common.
The name of intervention was led by "Quality-of-Life Assessment" (66 trials), "Laboratory Biomarker Analysis" (53 trials), "Questionnaire Administration" (42 trials), "Computed Tomography" (33 trials) and "Carboplatin" (30 trials). Other intervention names were less common.
Clinical Trials Genders at Sanford Joe Lueken Cancer Center
The vast majority of trials in "Sanford Joe Lueken Cancer Center" are
153 trials for "All" genders, 30 trials for "Female" genders and 6 trials for "Male" genders.
Clinical Trials Status at Sanford Joe Lueken Cancer Center
Currently, there are NaN active trials in "Sanford Joe Lueken Cancer Center".
undefined are not yet recruiting,
65 are recruiting,
96 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 16 completed trials in Sanford Joe Lueken Cancer Center,
7 suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Sanford Joe Lueken Cancer Center, 4 "Phase 1"
clinical trials were conducted, 85 "Phase 2" clinical
trials and 107 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 7 trials that are defined as “Not Applicable".